Completed PHASE1/PHASE2 INTERVENTIONAL NCT00004901

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer

A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Head and Neck Cancer

Interventions ethynyluracil fluorouracil hydroxyurea radiation therapy

Updated 5 times since 2017 Last updated: Jun 25, 2013 Started: Oct 31, 1999 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004901, this PHASE1/PHASE2 trial focuses on Head and Neck Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 5 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Robert H. Lurie Cancer Center

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States